REGENXBIO Inc.
9804 Medical Center Drive
Rockville, MD 20850
United States
240 552 8181
https://www.regenxbio.com
版塊: Healthcare
行業: Biotechnology
全職員工: 344
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Kenneth T. Mills | President, CEO & Director | 1M | 720.99k | 1975 |
| Mr. Vittal K. Vasista | Executive VP & CFO | 666.5k | 573.3k | 1968 |
| Mr. Curran M. Simpson M.S. | Executive VP & COO | 698.6k | 無 | 1962 |
| Dr. Olivier Danos Ph.D. | Executive VP & Chief Scientific Officer | 778.85k | 無 | 1958 |
| Dr. Stephen Pakola M.D. | Executive VP & Chief Medical Officer | 674.05k | 無 | 1969 |
| Mr. Patrick J. Christmas II, J.D. | Executive VP & Chief Legal Officer | 1.11M | 1.29M | 1971 |
| Ms. Shiva G. Fritsch | Chief Communications & People Officer | 無 | 無 | 無 |
| Dr. Laura A. Coruzzi J.D., Ph.D. | Executive Vice President of Intellectual Property | 無 | 無 | 1954 |
| Dr. Ram Palanki Pharm.D. | Executive VP of Commercial Strategy & Operations | 無 | 無 | 1976 |
描述
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
公司管治
截至 2024年5月1日 止，REGENXBIO Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：3；董事會：8；股東權利：8；現金賠償：8。
